TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27119829

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day co-administered with atorvastatin 20 mg
Number of subjects: 323

Group type: COMPARATOR
Intervention: Doubling atorvastatin dose
Number of subjects: 323
Study: 24508320

Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus treatment as usual
Number of subjects: 74

Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 74
Study: 22395889

Group type: EXPERIMENTAL
Intervention: Initiation of ocular hypotensive medication
Number of subjects: 432
Study: 21299153

Group type: EXPERIMENTAL
Intervention: 10F Double Layer Stent (DLS) (n = 24)
Number of subjects: 49

Group type: COMPARATOR
Intervention: 10F Tannenbaum Stent (TAN) (n = 25)
Number of subjects: 49
Study: 17343552

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) at low, medium, and high doses
Number of subjects: 16
Study: 16458538

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (30 or more drinks per month)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet soda consumption (one or more drinks per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet soda consumption
Number of subjects: 0
Study: 12924682

Group type: EXPERIMENTAL
Intervention: Process-experiential psychotherapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cognitive-behavioral psychotherapy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 66
Study: 10578595

Group type: EXPERIMENTAL
Intervention: Composite Indian herbal preparation (CIHP)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 8694025

Group type: EXPERIMENTAL
Intervention: Lactose supplementation (0.6 to 1.0 g.kg‐1.d‐1, divided into three doses) for 10 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dextrose supplementation for 10 days (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lactose challenge (0.35 g/kg) after overnight fast
Number of subjects: 20
Study: 1928975

Group type: EXPERIMENTAL
Intervention: n-of-1 RCT
Number of subjects: 26
Study: 6318345

Group type: EXPERIMENTAL
Intervention: 300 mg per day ketoprofen alone
Number of subjects: 18

Group type: COMPARATOR
Intervention: 300 mg per day ketoprofen combined with 1,500 mg aspirin
Number of subjects: 18
Study: 30387015

Group type: EXPERIMENTAL
Intervention: High intensity interval training (12 weeks, 3 sessions/week)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 26
Study: 27684415

Group type: EXPERIMENTAL
Intervention: Non-invasive high-frequency ventilation (NIHFV)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Bi-phasic continuous positive airway pressure (BP-CPAP)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: NIHFV
Number of subjects: 39

Group type: COMPARATOR
Intervention: BP-CPAP
Number of subjects: 39
Study: 26384629

Group type: EXPERIMENTAL
Intervention: Music therapy (listening to a recorded CD of music and songs preferred by the child)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (listening to a blank CD)
Number of subjects: 50
Study: 23790566

Group type: EXPERIMENTAL
Intervention: D-amphetamine (0, 5, 10, and 20 mg)
Number of subjects: 165
Study: 21283923

Group type: EXPERIMENTAL
Intervention: Higher fluence (HF) (3.8 J/cm2)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Lower fluence (LF) (2.5 J/cm2)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both LF and HF treatments
Number of subjects: 46
Study: 19135671

Group type: COMPARATOR
Intervention: Glimepiride (4 mg od)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg od)
Number of subjects: 28
Study: 17357473

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 0
Study: 15380894

Group type: EXPERIMENTAL
Intervention: 250 mg plain release ascorbic acid and 91 mg plain release d-alpha-tocopheryl acetate
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 250 mg slow release ascorbic acid and 91 mg plain release d-alpha-tocopheryl acetate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 11887109

Group type: COMPARATOR
Intervention: Concentric training (CON, n = 9)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Concentric-eccentric training (CON-ECC, n = 8)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Nontreatment (NONTX, n = 6)
Number of subjects: 23
Study: 9540144

Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextrophan (metabolite of dextromethorphan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capsaicin-induced hyperalgesia
Number of subjects: 0
Study: 8062609

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg/day) for 48 months in normotensive patients (NE group)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg/day) for 48 months in well-controlled hypertensive patients (HE group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No enalapril treatment in normotensive patients (NC group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No enalapril treatment in well-controlled hypertensive patients (HC group)
Number of subjects: 52
Study: 2643042

Group type: EXPERIMENTAL
Intervention: iopamidol (nonionic)
Number of subjects: 443

Group type: COMPARATOR
Intervention: diatrizoate (ionic)
Number of subjects: 443
Study: 797515

Group type: EXPERIMENTAL
Intervention: Oral administration of nickel (double-blind test)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intense handling of nickel-contaminated metal objects
Number of subjects: 12
Study: 31175814

Group type: EXPERIMENTAL
Intervention: Active Music Therapy (MT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Passive Music Therapy (MT)
Number of subjects: 16
Study: 28364446

Group type: EXPERIMENTAL
Intervention: Sleep Health Program (SHP) including sleep health education and sleep disorders screening
Number of subjects: 1189

Group type: EXPERIMENTAL
Intervention: Attendance at education sessions
Number of subjects: 1189

Group type: COMPARATOR
Intervention: Standard practice (control)
Number of subjects: 1189
Study: 25387489

Group type: EXPERIMENTAL
Intervention: 12-week multivariate aerobic training program
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nontrained group
Number of subjects: 39
Study: 23352954

Group type: EXPERIMENTAL
Intervention: High-Resistance Circuit (HRC) training
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Traditional Heavy Strength (TS) training
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 37
Study: 21289017

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium infusion (20‐mmol (5 g) magnesium sulfate for 5 consecutive days)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 19284575

Group type: EXPERIMENTAL
Intervention: Risk score for cervicitis diagnosis
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Gynecological examination (including friability)
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Prevalence of C. trachomatis
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Prevalence of N. gonorrhoeae
Number of subjects: 914
Study: 17202010

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg (n = 25)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Clonidine 3 microg kg(‐1) (n = 25)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (n = 25)
Number of subjects: 75
Study: 15130043

Group type: EXPERIMENTAL
Intervention: Delaire facemask and Bionator III appliance
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (untreated Class III malocclusions)
Number of subjects: 30
Study: 11524307

Group type: EXPERIMENTAL
Intervention: Acamprosate (two 333 mg tablets given three times daily for 180 days)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study: 9773133

Group type: EXPERIMENTAL
Intervention: Triple epidural mixture with adrenaline (bupivacaine 1 mg/ml, fentanyl 2 micrograms/ml, adrenaline 2 micrograms/ml)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Epidural infusion without adrenaline
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Triple epidural mixture with adrenaline
Number of subjects: 24
Study: 7824963

Group type: EXPERIMENTAL
Intervention: Deuterium-labeled DS (dermatan sulfate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Native heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzymatic degradation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemical degradation
Number of subjects: 0
Study: 2369494

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 50 mg/day
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Amiloride 5 mg twice daily
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 1015603

Group type: EXPERIMENTAL
Intervention: Linear analogue rating (10, 15, and 20 cm lines)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pethidine 150 mg intramuscularly
Number of subjects: 0
Study: 31686249

Group type: EXPERIMENTAL
Intervention: SIB-IMRT (67.5 Gy, 2.25 Gy/fraction)
Number of subjects: 69

Group type: COMPARATOR
Intervention: S-IMRT (70 Gy, 2 Gy/fraction)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: SIB-IMRT
Number of subjects: 69

Group type: COMPARATOR
Intervention: S-IMRT
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Distant metastasis-free survival
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Locoregional-free survival
Number of subjects: 69
Study: 30847839

Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Brain Health Program (BHP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Wait-list (WAIT) control group
Number of subjects: 25
Study: 27012822

Group type: EXPERIMENTAL
Intervention: Exercise group (8-week aerobic exercise programme plus usual medical care)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (usual medical care)
Number of subjects: 50
Study: 25956385

Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression (ASAD)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Active monitoring with specialist reassessment (AMSR)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Investigational shoulder arthroscopy only (AO)
Number of subjects: 300
Study: 23379271

Group type: EXPERIMENTAL
Intervention: ToM Intervention (ToMI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Active Control Group (ACG)
Number of subjects: 30
Study: 21746944

Group type: EXPERIMENTAL
Intervention: Posaconazole 100 mg QD for 24 weeks
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Posaconazole 200 mg QD for 24 weeks
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Posaconazole 400 mg QD for 24 weeks
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Posaconazole 400 mg QD for 12 weeks
Number of subjects: 146
Study: 18728054

Group type: EXPERIMENTAL
Intervention: Six‐month supervised aerobic and strength training
Number of subjects: 115
Study: 17719940

Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (follow-up alone)
Number of subjects: 26
Study: 15243282

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Non-hormone therapy (non-HT)
Number of subjects: 136
Study: 11044778

Group type: EXPERIMENTAL
Intervention: Clinical FC severity scale
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Variability in attentional performance
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Slow EEG rhythms across 90 s, 1 h and 1 week
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clinical ratings of FC
Number of subjects: 40
Study: 9388905

Group type: EXPERIMENTAL
Intervention: High dose vaccine (5 mg rBS and 10^8 WC)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Low dose vaccine (1 mg rBS and 10^8 WC)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 369
Study: 1414052

Group type: EXPERIMENTAL
Intervention: PEG solution (Oralav)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ringer's lactate solution (control group)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study: 2578107

Group type: EXPERIMENTAL
Intervention: Verapamil (150 micrograms/kg intravenous bolus followed by 150 micrograms/kg/hr intravenous infusion)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 35
Study: 31561278

Group type: EXPERIMENTAL
Intervention: sirolimus
Number of subjects: 238

Group type: COMPARATOR
Intervention: MMF
Number of subjects: 238
Study: 31649376

Group type: EXPERIMENTAL
Intervention: Daily mud packs and bicarbonate-alkaline mineral water baths
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Thermal hydrotherapy rehabilitation scheme
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Combination of mud packs and thermal hydrotherapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual medication only
Number of subjects: 66
Study: 30155979

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (600 mg)
Number of subjects: 699

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 699
Study: 27325147

Group type: EXPERIMENTAL
Intervention: CT-based treatment (n=92; 46 adrenalectomy, 46 mineralocorticoid receptor antagonist)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: AVS-based treatment (n=92; 46 adrenalectomy, 46 mineralocorticoid receptor antagonist)
Number of subjects: 200

Group type: COMPARATOR
Intervention: CT-based adrenalectomy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: AVS-based adrenalectomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: CT-based treatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: AVS-based treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: AVS compared to CT
Number of subjects: 200
Study: 24957302

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 175

Group type: COMPARATOR
Intervention: Matched control (American Lung Association's Freedom From Smoking program)
Number of subjects: 175
Study: 22056854

Group type: EXPERIMENTAL
Intervention: Doxorubicin 60 mg/m2 + Cyclophosphamide 600 mg/m2 every 21 days for four cycles
Number of subjects: 181

Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin 35 mg/m2 + Cyclophosphamide + Trastuzumab 2 mg/kg weekly for 12 weeks
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 181

Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Number of subjects: 181
Study: 19041197

Group type: EXPERIMENTAL
Intervention: CBT4CBT (computer-based training for CBT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: TAU (treatment-as-usual)
Number of subjects: 73
Study: 17258146

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day) + resistance exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 15059509

Group type: EXPERIMENTAL
Intervention: Isoflurane induced hypotension (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane maintained anesthesia (group B)
Number of subjects: 30
Study: 12042982

Group type: EXPERIMENTAL
Intervention: Doxorubicin (70 mg/m²) plus Ifosfamide (5 g/m²) followed by radiotherapy (chemotherapy arm)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Etoposide (250 mg/m²) + Ifosfamide (6 g/m²) + Doxorubicin (50 mg/m²) within 12 weeks (chemotherapy arm)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Etoposide (250 mg/m²) + Ifosfamide (6 g/m²) + Doxorubicin (50 mg/m²) combined with regional hyperthermia (RHT + chemotherapy arm)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Radiotherapy alone with no further treatment (observation arm)
Number of subjects: 370
Study: 9667341

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 60
Study: 7814832

Group type: EXPERIMENTAL
Intervention: Oral GHBA administration
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral GHBA and i.v. flumazenil administration
Number of subjects: 9

Group type: COMPARATOR
Intervention: Oral placebo and i.v. saline administration
Number of subjects: 9
Study: 2761740

Group type: EXPERIMENTAL
Intervention: Defibrotide alone or in addition to conventional therapies
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Defibrotide with conventional therapies
Number of subjects: 140
Study: 772696

Group type: EXPERIMENTAL
Intervention: pemoline
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 29701814

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 35
Study: 28145801

Group type: EXPERIMENTAL
Intervention: 2′MOE ASOs
Number of subjects: 2638
Study: 25739031

Group type: EXPERIMENTAL
Intervention: Ethinyl-estradiol 0.03 mg + Drospirenone 3 mg (EE + DRSP)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Ethinyl-estradiol 0.03 mg + Chlormadinone acetate 2 mg (EE + CMA)
Number of subjects: 106
Study: 23609610

Group type: EXPERIMENTAL
Intervention: 5‐HTP (three 50‐mg capsules)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 21270376

Group type: EXPERIMENTAL
Intervention: Calorie information
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Tax of ≥25% on high-calorie foods
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Price increase for high-calorie foods (125% and 150% of base price)
Number of subjects: 178

Group type: COMPARATOR
Intervention: No calorie information
Number of subjects: 178
Study: 19952467

Group type: EXPERIMENTAL
Intervention: Triple therapy (aspirin 100 mg, clopidogrel 75 mg, and triflusal 300 mg per day)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Dual therapy (aspirin 100 mg and clopidogrel 75 mg per day)
Number of subjects: 190
Study: 17457600

Group type: EXPERIMENTAL
Intervention: 3D ultrasound
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2D ultrasound
Number of subjects: 60
Study: 15473126

Group type: COMPARATOR
Intervention: Diet + Orlistat (group 1; n = 30 patients)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Diet + Sibutramine (group 2; n = 29 patients)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Diet + Orlistat + Sibutramine (group 3; n = 30 patients)
Number of subjects: 89
Study: 10676676

Group type: EXPERIMENTAL
Intervention: Garlic treatment (300 mg three times a day for three months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: COMPARATOR
Intervention: Garlic treatment or Placebo in LDL pattern A subjects
Number of subjects: 50
Study: 9377680

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy to maximal dose 6000 cGy (group I)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Short radiotherapy (4 x 500 cGy) (group II)
Number of subjects: 54
Study: 8462377

Group type: EXPERIMENTAL
Intervention: benfluorex
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 3080173

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen at 2 atmospheres absolute
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 31631033

Group type: EXPERIMENTAL
Intervention: Targeted PA message
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-inclusive PA message
Number of subjects: 60

Group type: COMPARATOR
Intervention: No youth PA message
Number of subjects: 60
Study: 30514278

Group type: EXPERIMENTAL
Intervention: Flipped Classroom (FC) e-learning program
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (no access to e-learning program)
Number of subjects: 212
Study: 26900092

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) with 66 Gy in 24 fractions and daily low dose cisplatin
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Log10(Volume) of primary tumor and lymph nodes
Number of subjects: 226
Study: 25710563

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 23088285

Group type: EXPERIMENTAL
Intervention: Newly defined clinical pathway
Number of subjects: 50
Study: 21915516

Group type: EXPERIMENTAL
Intervention: 1.23% acidulated phosphate fluoride gel, pH 4.1
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 3% potassium oxalate gel, pH 4.1 (Oxa-Gel®)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: iron sulfate gel (10 mmol/L FeSO4), pH 4.1
Number of subjects: 36

Group type: COMPARATOR
Intervention: Presence of smear layer
Number of subjects: 36
Study: 19033181

Group type: EXPERIMENTAL
Intervention: Intensive recommended treatment and lifestyle advice in cardiovascular prevention (observational design)
Number of subjects: 12500

Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acid (randomized controlled trial design)
Number of subjects: 12500
Study: 16556241

Group type: EXPERIMENTAL
Intervention: Chronic Migraine (CM)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Probable Chronic Migraine (PCM) and Probable Analgesic-Abuse Headache (PAAH)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Primary Fibromyalgia Syndrome (PFMS)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control Subjects
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Correlation between CSF values of GDNF and somatostatin in CM
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Correlation between CSF values of GDNF and somatostatin in PCM + PAAH
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Correlation between CSF values of GDNF and somatostatin in PFMS
Number of subjects: 71
Study: 14636820

Group type: EXPERIMENTAL
Intervention: Stress manipulation (speech task)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonstress control condition (magazine reading)
Number of subjects: 100
Study: 10068846

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 8523015

Group type: EXPERIMENTAL
Intervention: Intraoperative and postoperative Cell‐Saver (Haemonetics, Braintree, MA)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Postoperative Solcotrans (Smith & Nephew Richards, Memphis, TN) reinfusion protocol
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Closed‐suction Hemovac drain (Zimmer, Warsaw, IN)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: No drain used
Number of subjects: 153